Global Ventricular Tachycardia Pipeline Review, H2 2018 – Therapeutic Analysis of 6 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ventricular
Tachycardia – Pipeline Review, H2 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Ventricular Tachycardia – Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for
Ventricular Tachycardia (Cardiovascular), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews
of key players involved in therapeutic development for Ventricular
Tachycardia and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes; the molecules developed by Companies
in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 1
and 4 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision-making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Ventricular Tachycardia – Overview
  4. Ventricular Tachycardia – Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Ventricular Tachycardia – Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Ventricular Tachycardia – Companies Involved in Therapeutics
    Development
  • Audentes Therapeutics Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International LLC
  • InCarda Therapeutics Inc
  • Milestone Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/34hts4/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.